Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective

Journal of Pharmaceutical Sciences(2020)10.1016/j.xphs.2020.11.019Source: DataRank Database

Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective is a research paper published in Journal of Pharmaceutical Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.34)OA: bronzeTopics (64)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Linxi Zhu ORCID,Weixian Lin,Alexander Nguyen ORCID,Rodney J. Y. Ho ORCID,Simone Perazzolo ORCID

Live enrichment

PubMed:33248057 PMC:PMC7689305 OpenAlex:https://openalex.org/W3108313233

NIAID NIH HHS

Grant: UM1 AI120176

NIAID NIH HHS

Grant: R61 AI149665

NIAID NIH HHS

Grant: R33 AI149665

National Institutes of Health

Grant: 5R33AI149665-04

NextGen Long-acting and targeted combination ART for Children with HIV

National Institutes of Health

Grant: 1UM1AI120176-01

Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)

Foundation for the National Institutes of Health

FWCI

0.34

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

bronzeLicense: Elsevier TDM

journalhttp://jpharmsci.org/article/S0022354920307486/pdf

publisherhttp://jpharmsci.org/article/S0022354920307486/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0022354920307486?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022354920307486?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.xphs.2020.11.019

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and Effects0301 basic medicine03 medical and health sciencesAntiviral AgentsArtificial IntelligenceCOVID-19Cytokine Release SyndromeDrug RepositioningHumansImmunologic FactorsModels, BiologicalPharmacology, ClinicalSARS-CoV-2Translational Research, BiomedicalViral LoadVirus InternalizationCOVID-19 Drug Treatment

MeSH Terms

Cytokine Release SyndromeCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAntiviral AgentsArtificial IntelligenceHumansImmunologic FactorsModels, BiologicalPharmacology, ClinicalViral LoadVirus InternalizationTranslational Research, BiomedicalDrug Repositioning

Keywords

MedicineCytokine stormIntensive care medicineCoronavirus disease 2019 (COVID-19)DiseaseDrugContagious diseaseDrug developmentPharmacologyInfectious disease (medical specialty)Internal medicinePharmacokineticsModelingLong-actingSystems PharmacologyCovid-19Sars-cov-2Drug RepositioningPharmaceutical ScienceViral LoadVirus InternalizationAntiviral AgentsModels, BiologicalCOVID-19 Drug TreatmentTranslational Research, BiomedicalArtificial IntelligencePerspectivePharmacology, ClinicalHumansImmunologic FactorsCytokine Release Syndrome

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being